HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly unlikely to prevail in cefaclor patent suit, court rules; preliminary injunction against Ivax, Lederle denied.

Executive Summary

LILLY "NOT LIKELY TO SUCCEED" IN CEFACLOR PATENT SUIT, COURT STATES in denying Lilly's request for a preliminary injunction against generic cefaclor marketing by Ivax, Biocraft and Lederle. The Indianapolis federal court denied Lilly's petition on Aug. 4. Lilly had requested a preliminary injunction to prevent the three firms from marketing a generic version of its antibiotic Ceclor as part of a patent infringement suit.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel